{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-202719","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2022-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.914214+00:00","generated_at":"2026-06-24T08:16:26.899335+00:00","sec_items":["1.01","7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AlloVir raises $126.6M in registered direct offering at $4.61/share for Phase 3 trials","bullets":["Sold 27.46M shares at $4.61 each; gross proceeds ~$126.6M.","Funds to complete enrollment and data readouts in three ongoing Phase 3 trials of posoleucel.","New investors include Kite (Gilead), F2 Ventures, ElevateBio, Invus, Redmile, EcoR1 Capital, GMT Capital.","Offering expected to close July 28, 2022; no underwriter. Cash & equivalents $172.7M as of June 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-202719","json":"https://secwatch.observer/filing/0001193125-22-202719.json","markdown":"https://secwatch.observer/filing/0001193125-22-202719.md","text":"https://secwatch.observer/filing/0001193125-22-202719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522202719/0001193125-22-202719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522202719/d286495d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:16:26.899335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}